Shares of Vaxcyte Inc. (PCVX) have fallen roughly 64% from their 52-week high of $116, recorded last November, to around $42. As the company nears a significant near-term milestone for one of its drug candidates, could this spark a recovery in its stock and attract renewed investor interest?
The clinical-stage vaccine innovation company is focused on developing a pipeline of pneumococcal conjugate vaccine (PCV) candidates under clinical development, along with preclinical-stage programs targeting Group A Streptococcus and Shigella.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.